

20 **Abstract**

21 **Objectives:** A screening tool for substance use disorders is most needed for
22 patient care and referral. The study aims to develop the Substance Use Disorder
23 Screening Test (SUDST) to classify the severity of substance use disorders
24 based on the Fifth Edition of the Diagnostic and Statistical Manual of Mental
25 Disorders (DSM-5).

26 **Methods:** Eleven items of the SUDST, developed based on the DSM-5, were
27 tested on 207 participants who were receiving treatment for methamphetamine
28 use. Participants were interviewed with the SUDST, the screening test of the
29 Ministry of Public Health Version 2 (V.2), the Mini International Neuropsychiatric
30 Inventory (M.I.N.I) and were clinically diagnosed by attending psychiatrists.

31 **Results:** Cronbach's alpha coefficient was 0.79. The SUDST was highly
32 significantly associated with the M.I.N.I., V.2, and the clinical diagnosis ($p <$
33 0.001). Factor analysis showed three components: 1) preoccupation and loss of
34 control 2) risky/harmful use and 3) impact to bio-psychosocial aspects. Of the
35 total score of 11, the cut-off points to identify severe, moderate, and mild levels of
36 risk were ≥ 7 , 5-6, and 3-4, respectively with sensitivity = 72.7%-96.5% and
37 specificity = 61.9%-88.7%.

38 **Conclusions:** The SUDST had high reliability and validity that could be used for
39 screening risk for substance use disorders.

40

41 **Key words:** Addiction, diagnosis, DSM, psychostimulants, scale development

42

43

44 **Introduction**

45

46 Substance use has caused problems in all continents around the world, affecting
47 individuals, families, communities, and societies. In the South East Asian countries,
48 the most common illicit substance use was cannabis, kratom, and
49 methamphetamine (1-3), which the latter (commonly known as speed pill (yaba)
50 and crystal meth (ice)) caused the most problem in the region. The Princess Mother
51 National Institute for Drug Abuse Treatment (PMNIDAT), the first and largest
52 treatment center for substance use disorders in Central Thailand and in the South
53 East Asia with 600 in-patient bed capacities, reported statistics which showed
54 nearly half of the patients having methamphetamine use disorder (4), which has
55 been increasing each year from 40.26% in 2016, increasing to 46.39% in 2017,
56 and to 54.35% in 2018. Most of the inpatients with methamphetamine use disorder
57 in this treatment center had a history of psychiatric symptoms including anxiety or
58 suspiciousness (91.2%), depression (86.8%), and hallucination (85.7%) (5).

59

60 An effective and user-friendly assessment tool for substance use disorders is most
61 needed for patient care and referral to the allocated treatment settings for patient
62 management. Treatment facilities for substance use disorder in Thailand has used
63 The Ministry of Public Health's Screening Test Version 2 (V.2), which was adapted
64 from the World Health Organization (WHO)'s Alcohol, Smoking, and Substance
65 Involvement Screening Test (ASSIST) (6, 7). The V.2 has been used to assess
66 levels of risk of substance use for allocating persons who used substance to each
67 level of the formal treatment settings in Thailand. Persons who had low risk from
68 the screening test were usually referred to the outpatient treatment at the general,

69 provincial, or district hospitals with service for persons who used substances while
70 those with moderate risk were usually sent to the treatment program at the
71 designated government locations in each province that was operated in
72 collaboration between the Ministry of Public Health, Ministry of Defense, and
73 Ministry of Justice, and Ministry of Interior (8). For people with high risk of
74 methamphetamine use disorder as screened by the V.2 were usually sent to the
75 inpatient treatment at the substance treatment facilities widely spread over four
76 parts of Thailand.

77

78 In 2013, the American Psychiatric Association issued the Fifth Edition of the
79 Diagnostic and Statistical Manual for Mental Disorder (DSM-5) (9) that view the
80 substance use problems as a continuum of disorder from mild, moderate to severe
81 substance use disorder. As such, the DSM-5 diagnosis for substance use
82 disorders, especially methamphetamine, the most problematic illegal substance in
83 the region, has never been tested or compared to the Thai V.2. In the study, we
84 compared the DSM-5 criteria for substance use disorders with the current formal
85 use of V.2, which is the main screening tool for allocating persons with illegal
86 problems in Thailand to receive treatment by using the Substance Use Disorder
87 Screening Test (SUDST), that had been newly developed based on the DSM-5
88 criteria symptoms. The SUDST was then tested in the study for validity and
89 reliability with clinical diagnosis by clinicians and the Mini International
90 Neuropsychiatric Interview (M.I.N.I.). The study aims to investigate the reliability
91 and validity of this new screening tool for clinical substance use disorder based on
92 DSM-5 criteria. The new instrument may be used accordingly with other personal

93 and societal factors for allocating persons who use substance to get appropriate
94 treatment for substance use based on their needs.

95

96 **Methods**

97

98 Two-hundreds and seven male and female patients aged 13 years and over
99 receiving outpatient service for methamphetamine use from the PMNIDAT and
100 its satellite hospitals in the four regions of Thailand including Central (PMNIDAT
101 or Thanyarak Pathumthani), North (Thanyarak Chiang Mai), Northeast
102 (Thanyarak Khon Kaen), and South (Thanyarak Songkla) were interviewed
103 between August 2017 to December 2018 by attending psychiatrists for DSM-5
104 substance use disorder diagnosis. All of them had at least 3 years experience in
105 addiction treatment. The attending psychiatrists were blinded to the diagnosis
106 made by the questionnaires used in the study. Risk and methamphetamine use
107 disorder were obtained using the SUDST, the M.I.N.I. for methamphetamine use
108 disorder and the V.2 by research nurses (with at least 5 years experience in
109 addiction treatment). All interviewers attended a training class for M.I.N.I.,
110 SUDST, and V.2. Individuals with cognitive impairment or psychosis (e.g.,
111 history of being diagnosed with dementia, psychotic disorder) were excluded
112 from the study. The study has been approved by the Ethics Committee of the
113 PMNIDAT with study number: 59023.

114

115 The SUDST were developed from the DSM-5 criteria for substance use
116 disorders (9). The test had 11 items for the respondent to answer yes or no to
117 each question that correspond to what participants have experienced in the past

118 12 months of their substance use. The test was examined for content validity
119 from 5 experts in the fields of addiction, behavioral science, and psychometric
120 test. The Index of Item-Objective Congruence is 0.65. The screening tool was
121 then adjusted per suggestion and tested in 30 subjects (10) with substance use.
122 The language was then further adjusted based on suggestion from this initial field
123 testing. The language-adjusted screening test was then tested for inter-rater
124 reliability by two independent interviewers with the time interval not more than 1
125 week apart. The content of the screening test includes four aspects of addiction
126 including impaired control of substance use, social impairment from substance
127 use, risky use of substance, and the pharmacological aspect of addiction.

128

129 The V.2 is the screening tool for referral persons with substance use problems in
130 Thailand. It was developed by the Ministry of Public Health (MOPH) and was
131 known as “Screening Form – MOPH: Version 2” or V.2 in brief. The test was
132 adapted from the World Health Organization (WHO)’s Alcohol, Smoking, and
133 Substance Involvement Screening Test (ASSIST), comprising of 6 questions
134 related to behaviors of substance use, the impact of substance use, and the
135 concern from others about one’s substance use in the past 3 months. Each item
136 has 5 answer options from never, only 1-2 times total, about 1-3 times per month,
137 about 1-4 days per week, and 5-7 days per week (almost every day) The total
138 score was categorized to three levels (e.g., mild, moderate, and severe) risk for
139 substance dependence.

140

141 The M.I.N.I., Methamphetamine Section, Thai version was adapted for the
142 diagnosis of DSM-5 Substance Use Disorder in the study by R.K. and colleagues.

143 The original Thai M.I.N.I had two parts for substance diagnoses based on DSM-
144 IV criteria to diagnose methamphetamine dependence (7 items) and
145 methamphetamine abuse (4 items). In the current study, the item related to legal
146 problem from substance use was excluded from algorithm of diagnosis and
147 replaced by an item related to craving for substance in order to correspond to the
148 DSM-5 criteria for substance use disorder. Having 2-3, 4-5, and 6 or more criteria
149 mean having mild, moderate, or severe level of substance use disorders.

150

151 Data from all questionnaires were checked for completeness by a researcher.
152 The total duration of data collection was 16 months. First we tested for reliability
153 of the SUDST by using Cronbach's alpha coefficient for internal consistency.
154 Concurrent validity of the questionnaire for DSM-5 diagnosis for substance use
155 disorder was tested by using contingency coefficient with the clinical diagnosis. In
156 addition, construct validity was tested by using Factor analysis. Finally, the
157 SUDST was tested to determine the cut off point for the risk of having substance
158 use disorder as provided by clinicians' judgment. Cut off points for differentiating
159 levels of substance use disorders were analyzed by using area under the
160 receiver operating characteristic (ROC) curve to have sensitivity and specificity
161 values of the SUDST, the new screening tool for clinical substance use disorder
162 based on DSM-5 criteria.

163

164 **Results**

165 Table 1 shows demographics of the participants in the study. Of 207 participants,
166 most were male (88.4%), single (60.9%), and graduated from high school

167 (57.0%). The mean age was 29 years (SD = 8.3, Min = 14, Max = 53). Twenty-
 168 seven percent of the participants were unemployed and 67.1% had drug related
 169 offences in the past. Table 2 shows the substance use data. Most of the
 170 participants used methamphetamine and other illegal substances including
 171 cannabis and kratom (67.6%). About one-third (29.0%) used speed pills (yaba)
 172 only without any other illegal substance. The average daily amount of speed pills
 173 (yaba) consumed was 4 pills and the average duration of substance use was 7
 174 years. Most individuals who used crystal meth (ice) did not know the daily amount
 175 in grams.

176

177 **Table 1.** Demographic data of the participants in the study (N = 207).

	n (N = 207)	%
Gender		
Male	183	88.4
Female	24	11.6
Marital status		
Single	126	60.9
Married	65	31.4
Divorced, widow, separated	13	6.3
Do not answer	3	1.4
Age (years)	mean = 29 SD = 8.3 Min = 14 Max = 53	
≤19	27	13.0
20-29	89	43.0
30-39	66	31.9
40-49	21	10.2
≥50	4	1.9
Level of education		
None	1	0.5
Primary school	45	21.8
High school	118	57.0
Vocational school	28	13.5
Bachelor or graduate degree	15	7.2
Occupation		
Unemployed	56	27.0
Students	11	5.3
Employees	73	35.5
Farming / Fishery	16	7.6
Business owners	39	18.8
Government officers	10	4.8
Do not answer	2	1.0
Relationship in the family		
Good	117	56.5
No interaction / distant	21	10.1
Fight some times	63	30.5
Fight almost always	6	2.9
Drug offence (s)		
Ever	139	67.1
Never	68	32.9

178

179 **Table 2.** Substance and methamphetamine use data in the participants of the
 180 study.

	n (N = 207)	%
Substance use		
Speed pills (yaba) only	60	29.0
Crystal meth (ice) only	3	1.5
Speed pills and crystal meth only	4	1.9
Yaba/ice and other substances	140	67.6
Daily amount of yaba use (pills)		
	mean =4 SD = 5.1 Min =0.5 Max 48	
≤ 5	143	72.9
6-10	20	10.1
11-15	4	2.0
15 and above	2	1.0
Did not answer	29	14.0
Duration of yaba use (years)		
	mean =84 SD = 74.4 Min =12 Max 576	
≤ 5	104	52.5
6-10	45	22.7
11-15	25	12.6
16-20	15	7.6
20 or more	4	2.0
Did not answer	5	2.6
Daily amount of ice use (grams)		
< 1 gram	17	25.4
1 gram and more	4	5.9
Did not answer	46	68.7
Duration of ice use (years)		
	mean =36 SD = 49.9 Min =2 Max 240	
≤ 1	10	14.9
2-5	10	14.9
6 or more	2	2.9
Did not answer	45	67.3

181

182 Regarding reliability of the SUDST, Cronbach's alpha coefficient is 0.79 which
 183 reflects good internal consistency of the instrument but Cohen's kappa is only
 184 0.45 for inter-rater reliability. Construct validity was tested by using Factor
 185 analysis of the 11 questions used in the questionnaire and shown in Table 3.
 186 Extraction method was used with the Principal component analysis by the
 187 Varimax rotation. Three factors were found including preoccupation / loss of
 188 control of use comprising of 4 questions, Risky or harmful use comprising of 3
 189 questions, and the impact of use comprising of 4 questions. The correlation
 190 between each construct is in high level (more than 0.4). The factor loading could
 191 describe the variance at 51.8%. Specifically, Factor 1 could describe the variance
 192 at 32.3%, Factor 2 could describe at 10.1%, and Factor 3 could describe at 9.3%.
 193 Concurrent validity of the SUDST for Substance Use Disorder with other

194 measures including clinical diagnosis by physicians and the M.I.N.I., and the V.2
195 were high by using contingency coefficient ($p < 0.001$) (Table 4).

196

197 **Table 3.** Factor loading of the 11 items of the Substance Use Disorder Screening
198 Test (SUDST).

Factors	Item	Factor loading	
Factor 1 Preoccupation / loss of control of substance use	1	Used more than intention	0.72
	3	Spent a lot of time for substance	0.67
	2	Wanted to stop or cut down but unsuccessful	0.55
	4	Craving for substance	0.49
Factor 2 Risky / harmful use	9	Used despite the substance caused problems	0.73
	8	Used in risky situations	0.69
	10	Tolerance	0.54
Factor 3 Impact of use	11	Withdrawal symptoms	0.72
	6	Used despite having problems with others	0.69
	7	Decreased healthy recreational activities	0.66
	5	Used until impairment in work, school, or family	0.41

199

200 **Table 4.** Concurrent validity of the Substance Use Disorder Screening Test
201 (SUDST) with the M.I.N.I., V.2, and clinical diagnosis.

Measures	Coefficient	P-values
Mini international neuropsychiatric Inventory (M.I.N.I.)	.51	<.001
V.2	.57	<.001
Clinical/physician diagnosis based on DSM-5	.54	<.001

202

203

204 Table 5 shows cut off points of the SUDST to determine level substance use
205 disorder and categorize them into three groups based on clinical judgment
206 including low, moderate, and high risk of substance use disorder according to the
207 physician's judgement. The score at 7 or higher had high sensitivity (77.9%) and
208 specificity (72.7%) to determine the high risk group. The scores at 5 or 6 can
209 define the moderate risk group (sensitivity = 88.7%; specificity = 61.9%) and the

210 scores at 3 or 4 can define the low risk group (sensitivity = 96.5%, and specificity
211 = 66.7%). The Area Under the Curve (AUC) is in good ranges (0.83 - 0.87).

212

213 **Table 5.** Cut – off point for the Substance Use Disorder Screening Test (SUDST)
214 comparing to the clinical judgment based on DSM-5 criteria for substance use
215 disorders.

Level of substance use disorder	Cut-off point	Sensitivity	Specificity	Area under curve (95% CI)
Severe	≥7	77.9	72.7%	0.83 (0.76-0.90)
Moderate	5-6	88.7%	61.9%	0.87 (0.81-0.93)
Mild	3-4	96.5%	66.7%	0.85 (0.69-1.0)

216

217 Discussion

218 The SUDST is a screening test based on DSM-5 symptom criteria for substance
219 use disorders comprising of 11 questions regarding to the past 12 months
220 experience of substance use with yes or no answers. The score ranging from 0 to
221 11. It is suitable for addiction researchers/specialists to evaluate people who use
222 substance regarding to DSM-5 diagnosis of substance use disorder by using
223 DSM-5 diagnostic criteria or to evaluate risk of substance use especially
224 methamphetamine by using the new cut off point for clinical purposes such as
225 allocation of persons to specific settings (i.e. outpatient, inpatient, long-termed
226 rehabilitation) (8).

227

228 The reliability by internal consistency of the Thai SUDST instrument is in good
229 level with Cronbach's alpha coefficient = 0.79. Construct validity by Principal
230 component analysis found 3 factors covered 51.8% of the variance including

231 32.3%, 10.1% and 9.3%, for Factor 1 (preoccupation / loss of control), Factor 2
232 (risky and harmful use), and Factor 3 (impact of use), respectively. Concurrent
233 validity of the instrument is good when compared with three measures including
234 M.I.N.I., V.2, and clinical diagnosis/judgment ($P < 0.001$). In addition to using the
235 DSM-5 diagnostic criteria for substance use disorders, new scores of the
236 instrument could make cut off points able to divide subjects into three categories
237 comparable to the clinical judgment including high risk (score = 7 or more with
238 sensitivity = 77.9% and specificity = 72.7%), moderate risk (score = 5 - 6 with
239 sensitivity = 88.7% and specificity = 61.9%), and low risk (score = 3 - 4 with
240 sensitivity = 96.5% and specificity = 66.7%) with the AUC in good levels (0.83 -
241 0.87).

242

243 In the study, all of the participants used methamphetamine in the past 12 months
244 and 67% of them used it with other illegal substances. This proportion is
245 consistent with the annual information that more than 50% of the patients with
246 methamphetamine use disorders at the treatment centre used other illegal
247 substances in the past 12 months (4). Using more than one substance increase
248 harm and negative outcomes which might interfere with level of risk and result to
249 different result of the screening (11). We did not exclude participants who used
250 more than one substances in this study. However, including persons who used
251 other substances than methamphetamine reflects the real world situation that
252 would make the SUDST to be used generally.

253

254 Factor analysis of the SUDST revealed three components including
255 preoccupation or loss of control, risky/harmful use, and impact of use. The result
256 is consistent with other instruments related to measuring the severity or risk of
257 substance. For example, Khon Kaen University-Volatile Use Disorder
258 Identification Test (KKU-VOUDIT) (12), a ten-question questionnaire, comprised
259 of three components including intoxication or impact of use, preoccupation or loss
260 of control, and harmful use. Nevertheless, The DSM-5 diagnostic criteria for
261 substance use disorder suggested four components of the disorder including
262 impaired control, social impairment, risky use, and pharmacological component
263 (9). In general, preoccupation or loss of control over substance use is usually
264 considered to be the core symptoms of addiction by the definition of addiction
265 that continuing to use or seek for substances despite knowing that it causes harm
266 to oneself. Four items were in this core component to reflect the impaired control
267 including 1) using substance more than intended 2) unable to stop or cut down
268 substance use 3) spending a lot of time using/interacting with the substance and
269 4) craving for substance.

270

271 The pharmacological aspect has not appeared as a component in the study.
272 Specifically, the two questions reflecting the pharmacological aspect of substance
273 use disorder (e.g., tolerance and withdrawal) were each either included into the
274 component of risky / harmful use or in component of the impact of use. Regarding
275 the items for the component of risky/harmful use, they include 1) using substance
276 in a risky situation (i.e., driving, operating machinery) 2) using substance despite
277 knowing it causes physical, psychological, or other problems and 3) increasing
278 the amount of substance to get the same effect or experiencing reduced effect

279 while using the same amount of substance. It is understandable that tolerance of
280 a substance especially the question asking about increasing the amount of
281 substance in order to get the same effect may be viewed as risky/harmful use by
282 the persons who use substance.

283

284 Likewise, having withdrawal symptoms from methamphetamine, including fatigue,
285 hypersomnia, irritable or depressed mood may be viewed as negative impacts of
286 substance use and are included in the component of impacts of use. The other
287 items in this component include 1) regular use of substance until having impaired
288 function for work, study, or family 2) using substance despite it caused
289 interpersonal relationship (i.e., domestic violence, physical or verbal fights) and 3)
290 reduced social or recreational activities due to substance use.

291

292 Several limitations of the study deserve to be mentioned. The study took place in
293 addiction treatment settings so the most of the participants mostly had problems
294 from substance use and might not reflect those with milder level of substance
295 use. Further study should test the instrument in primary health care where more
296 persons with mild level or use without any level of substance use disorder would
297 be included. In addition, larger sample size would give more power to test the
298 instrument. People who use other substances including illegal substances (i.e.,
299 cannabis, kratom, opioids) or legal substances (i.e., alcohol, tobacco) should be
300 recruited to test the reliability and validity of the instrument.

301

302 By using the SUDST, as well as the risk assessment by the V.2 which has
303 already been formally used, the severity of the disorder is divided into three levels
304 of risk including mild, moderate, and severe. By doing so, substance use disorder
305 is viewed as a spectrum and not a binary of disease (e.g., abuse or dependence).
306 This work is in agreement with the ASSIST (7) and the DSM-5 diagnostic criteria
307 (9) (which is the basis of the SUDST). The SUDST cut-off point for the mild level
308 of the risk for substance use disorder has 97% sensitivity, making the instrument
309 a good candidate for screening persons with risky behavior of substance use to
310 the various level of severity and referral to an appropriate setting at the beginning
311 stages of the diseases. Therefore, the SUDST is an option to be used in health
312 care setting to differentiate the severity of substance use.

313 ***Acknowledgements***

314 We would like to thank Viroj Verachai, M.D. for facilitating the process of the
315 study. We would also like to thank all participants for their time and efforts. R.K.'s
316 research career is supported by the Centre for Addiction Studies (supported by
317 The Thai Health Promotion Foundation) and the R01 DA037974 and the D43
318 TW009087/TW/FIC NIH HHS, US.

319 ***Conflicts of interest statement:***

320 The authors report no conflicts of interest.

321 **References**

- 322 1. UNODC. World Drug Report 2021. United Nations publication; 2021.
323 Report No.: Sales No. E.21.XI.8.

- 324 2. Centre for Addiction Studies. Survey on substance uses and attitude
325 toward substances in the Thai population aged 15-65 years. Faculty of Medicine,
326 Chulalongkorn University, Bangkok; 2020.
- 327 3. Kanato M, Leyatikul P, Wonguppa R. Size estimation of substances users
328 population in Thailand 2019. ONCB journal. 2020;36(2):37-48.
- 329 4. Princess Mother National Institute on Drug Abuse Treatment. Statistics on
330 substance abuse treatment at the Princess Mother National Institute on Drug
331 Abuse Treatment in 2015-2019. Pathumtani; 2019.
- 332 5. Rukngan W, Singhtho T, Noikorn S, Phonsamrong S, Nuannum D,
333 Phajaroen S. Psychiatric symptoms in Amphetamine-Type stimulants (ATS) in-
334 patients at Thanyarak Institute. Thai Journal of Addiction. 2013;1:6-14.
- 335 6. Integrated Management of Alcohol Intervention program. The Alcohol,
336 Smoking and Substance Involvement Screening Test (ASSIST) Manual for use in
337 primary care, Thai version. Integrated Management of Alcohol Intervention
338 program; 2011.
- 339 7. World Health Organization. The Alcohol, Smoking and Substance
340 Involvement Screening Test (ASSIST) : Manual for use in primary care. World
341 Health Organization; 2010.
- 342 8. Narcotics Control Management Center Thailand Ministry of Public Health.
343 Strategic plan for substance abuse treatment and rehabilitation budget years
344 2021-2023. 2021.
- 345 9. American Psychiatric Association. Diagnostic and Statistical Manual of
346 Mental Disorders, Fifth Edition (DSM-5). Arlington, VA: American Psychiatric
347 Publishing; 2013.

- 348 10. Kongsomboon K. Textbook of edidemiological research for medical
349 students. Bangkok2014.
- 350 11. Australian Government Department of Health. Patterns of use and harms
351 associated with specific populations of methamphetamine users in Australia -
352 exploratory research. <https://www1.health.gov.au/>; 2008.
- 353 12. Arunpongpaisal S, Kanato M, Chiaviriyabunya I, Daosodsai S, Kamproa S.
354 Tools development and validity testing of Khon Kaen University-Volatile Use
355 Disorder Indentification Test (KKU-VOUDIT) to classify severity of volatile users.
356 J Psychiatr Assoc Thailand. 2010;55(1):63-78.
- 357